Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas

Clinically HER2+ (cHER2+) breast cancer (BC) can no longer be considered a single BC disease entity in terms of trastuzumab responsiveness. Here we propose a framework for predicting the response of cHER2+ to trastuzumab that integrates the molecular distinctions of intrinsic BC subtypes with recent...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin-Castillo, Begoña, Lopez-Bonet, Eugeni, Cuyàs, Elisabet, Viñas, Gemma, Pernas, Sonia, Dorca, Joan, Menendez, Javier A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741696/
https://www.ncbi.nlm.nih.gov/pubmed/26474458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741696/
https://www.ncbi.nlm.nih.gov/pubmed/26474458

Ejemplares similares